Uniphar PLC
LSE:UPR
Uniphar PLC
Uniphar Plc engages in the provision of pre-wholesale and wholesale pharmaceutical distribution. The company is headquartered in Dublin, Dublin and currently employs 2,920 full-time employees. The company went IPO on 2019-07-17. The firm is a diversified healthcare services company. The company serves multinational pharmaceutical and medical technology manufacturers across three divisions: Commercial & Clinical, Product Access and Supply Chain & Retail. Through commercial & clinical division, the Company provides sales, marketing and distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Product Access division offers two service offerings: On Demand Access and Exclusive Access. On Demand Access is a pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists. Exclusive Access is a manufacturer led solution for controlling the release of specialty medicines for specifically approved patient populations. Supply Chain & Retail provides both pre-wholesale distribution and wholesale distribution of pharmaceutical, healthcare and animal health products.
Uniphar Plc engages in the provision of pre-wholesale and wholesale pharmaceutical distribution. The company is headquartered in Dublin, Dublin and currently employs 2,920 full-time employees. The company went IPO on 2019-07-17. The firm is a diversified healthcare services company. The company serves multinational pharmaceutical and medical technology manufacturers across three divisions: Commercial & Clinical, Product Access and Supply Chain & Retail. Through commercial & clinical division, the Company provides sales, marketing and distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Product Access division offers two service offerings: On Demand Access and Exclusive Access. On Demand Access is a pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists. Exclusive Access is a manufacturer led solution for controlling the release of specialty medicines for specifically approved patient populations. Supply Chain & Retail provides both pre-wholesale distribution and wholesale distribution of pharmaceutical, healthcare and animal health products.
Strong Results: Uniphar delivered solid H1 2025 results with revenue of €1.5 billion, gross profit of €220 million, and EBITDA of €58 million.
Profit Growth: Organic gross profit grew by 8%, and earnings per share increased by 21%.
Investments Impact Margins: Upfront investments in technology, management, and new distribution centers are weighing on short-term EBITDA, notably in the Supply Chain & Retail division.
Divisional Performance: Pharma and Medtech divisions reported double-digit and high single-digit profit growth, respectively, while Supply Chain & Retail experienced modest profit growth but lower EBITDA due to investment.
Guidance & Outlook: Management reaffirmed confidence in double-digit growth for Pharma and high single-digit growth for Medtech, with expectations for overall stronger performance in H2 and medium-term EBITDA of €200 million by 2028.
Major Facility Investments: The new Irish distribution center will cost 10–15% more than previously planned, but is expected to quickly surpass return on capital targets and transform operational efficiency.
Geographic Expansion: Growth initiatives include expanding Medtech into the Nordics and Austria and scaling Pharma services in Europe and the U.S.
